Key Insights

Highlights

Success Rate

40% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

13.0%

3 terminated out of 23 trials

Success Rate

40.0%

-46.5% vs benchmark

Late-Stage Pipeline

9%

2 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed with results

Key Signals

3 with results40% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (2)
Early P 1 (1)
P 1 (6)
P 2 (10)
P 3 (2)

Trial Status

Recruiting10
Active Not Recruiting4
Terminated3
Completed2
Not Yet Recruiting1
Suspended1

Trial Success Rate

40.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07156227Phase 1RecruitingPrimary

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

NCT05136196Phase 2Recruiting

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

NCT03258554Phase 2CompletedPrimary

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

NCT03811015Phase 3Active Not Recruiting

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

NCT07195734Phase 2Recruiting

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

NCT05172245Phase 1RecruitingPrimary

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

NCT05541016Phase 2Recruiting

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

NCT05050162Phase 2Suspended

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

NCT06532279Phase 2Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT07441681Phase 3Not Yet Recruiting

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

NCT06356272RecruitingPrimary

Oropharynx (OPX) Biomarker Trial

NCT03010150Recruiting

Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer

NCT05232851Phase 1Active Not RecruitingPrimary

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

NCT04533750Phase 1Active Not Recruiting

Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin

NCT06914999Early Phase 1Recruiting

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT04900623Phase 2Recruiting

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

NCT04162873Phase 2TerminatedPrimary

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

NCT04576091Phase 1Active Not RecruitingPrimary

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

NCT04140513Not ApplicableWithdrawn

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

NCT04489212Not ApplicableCompleted

Study of Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration in HPV+ Head and Neck Cancer of Unknown Primaries

Scroll to load more

Research Network

Activity Timeline